Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal, Bruce; Perkovic, Vlado; W. Mahaffey, Kenneth; de Zeeuw, Dick; Fulcher, Greg; Erondu, Ngozi; Shaw, Wayne; Law, Gordon; Desai, Mehul; R. Matthews, David

doi:10.1056/nejmoa1611925

Public

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Published in New England Journal of Medicine • Jun 12, 2017

Authors:

Bruce Neal

Vlado Perkovic

Kenneth W. Mahaffey

Abstract

Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The CANVAS Progra...

Subject

Canagliflozin

Albuminuria

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!